GlassScriptPhysician profile
Ashley N Tyler
NPI 1063035632
$9,125.25
in general payments reported to CMS, 2019-2025
62 companies · $1,348 in 2025
The $1,348 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,591 · 2023: $3,393 · 2024: $2,794 · 2025: $1,348.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,157 · Education: $377.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,157.49 |
| Education | $376.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $916.43 | 2022-2025 | Kisqali, Piqray |
| Janssen Biotech, INC. | $651.45 | 2022-2025 | Darzalex, Talvey, Tecvayli |
| Pfizer INC. | $464.32 | 2022-2025 | |
| Gilead Sciences, INC. | $453.37 | 2025 | Biktarvy, Yeztugo |
| Incyte Corporation | $424.01 | 2022-2024 | Jakafi, Monjuvi, Pemazyre |
| Abbvie INC. | $415.61 | 2023-2025 | |
| Seagen INC. | $387.42 | 2022-2023 | Tukysa, Padcev, Tivdak |
| Dendreon Pharmaceuticals LLC | $360.83 | 2022-2025 | Provenge |
| Viiv Healthcare Company | $333.97 | 2024-2025 | Apretude, Cabenuva, Dovato |
| Bayer Healthcare Pharmaceuticals INC. | $288.68 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $275.69 | 2022-2025 | Keytruda, Lynparza, Welireg |
| Glaxosmithkline, LLC. | $239.79 | 2023-2025 | Jemperli, Zejula |
| Astrazeneca Pharmaceuticals LP | $224.02 | 2022-2025 | Enhertu, Tagrisso, Calquence |
| Pharmacyclics LLC, An Abbvie Company | $216.44 | 2022-2023 | Imbruvica |
| Karyopharm Therapeutics INC. | $193.66 | 2022-2025 | Xpovio |
Show all 62 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $180.09 | 2022-2025 | Iclusig, Ninlaro, Alunbrig |
| Celltrion USA INC. | $178.88 | 2023 | Vegzelma |
| Astellas Pharma US INC | $168.17 | 2023-2024 | Padcev |
| Regeneron Healthcare Solutions, INC. | $161.96 | 2023-2024 | Libtayo |
| Servier Pharmaceuticals LLC | $153.56 | 2022-2025 | |
| Lilly USA, LLC | $152.00 | 2022-2025 | Verzenio, Jaypirca, Retevmo |
| Puma Biotechnology, INC. | $136.37 | 2022-2024 | |
| Pharmacosmos Therapeutics INC. | $127.58 | 2022-2024 | Monoferric |
| Tersera Therapeutics LLC | $125.29 | 2022-2024 | Xermelo, Quzyttir |
| Ipsen Biopharmaceuticals, INC | $124.57 | 2022-2024 | Tazverik, Somatuline Depot, Onivyde |
| Taiho Oncology, INC. | $121.36 | 2023-2024 | |
| Eisai INC. | $111.83 | 2022-2024 | |
| Genentech USA, INC. | $106.20 | 2022-2024 | Tecentriq, Tecentriq Hybreza, Alecensa |
| Daiichi Sankyo INC. | $105.71 | 2022-2024 | Enhertu, Injectafer |
| Novocure INC. | $87.11 | 2022-2023 | Optune |
| Kite Pharma, INC. | $81.48 | 2023 | |
| Adaptive Biotechnologies Corporation | $79.50 | 2022-2025 | Clonoseq |
| Amgen INC. | $73.13 | 2022-2023 | Kyprolis |
| Genzyme Corporation | $69.85 | 2022-2023 | |
| Jazz Pharmaceuticals INC. | $67.07 | 2023-2024 | |
| Exelixis INC. | $66.04 | 2022-2024 | Cabometyx |
| Emd Serono, INC. | $61.33 | 2022-2023 | Tepmetko, Bavencio |
| Acrotech Biopharma INC. | $50.96 | 2023-2024 | Beleodaq |
| Blue Earth Diagnostics | $50.14 | 2023 | |
| Deciphera Pharmaceuticals INC. | $47.81 | 2023-2024 | Qinlock |
| Cti Biopharma Corp. | $45.51 | 2022-2023 | Vonjo |
| G1 Therapeutics, INC. | $44.54 | 2023 | Cosela |
| Pharming Healthcare, INC. | $44.37 | 2022-2024 | Ruconest |
| Pharmaessentia USA Corporation | $41.79 | 2022 | |
| Mirati Therapeutics, INC. | $40.36 | 2023 | Krazati |
| Celgene Corporation | $39.85 | 2023 | Pomalyst |
| Iovance Biotherapeutics, INC. | $31.82 | 2025 | Amtagvi |
| Organon LLC | $31.39 | 2022 | |
| Amneal Pharmaceuticals LLC | $29.30 | 2023-2024 | Avastin |
| Geron Corporation | $27.82 | 2024 | Rytelo |
| Stemline Therapeutics INC. | $25.97 | 2023 | Orserdu |
| Array Biopharma INC | $25.47 | 2024 | Tukysa, Ibrance |
| Beigene USA, INC. | $23.27 | 2023 | Brukinsa |
| Alexion Pharmaceuticals, INC. | $21.41 | 2022 | |
| Spectrum Pharmaceuticals INC. | $20.42 | 2023 | Rolvedon |
| Genmab U.S., INC. | $18.39 | 2023 | Epkinly |
| Legend Biotech USA INC. | $17.23 | 2024 | |
| Agios Pharmaceuticals, INC. | $15.16 | 2024 | Pyrukynd |
| Alnylam Pharmaceuticals INC. | $14.47 | 2023 | Givlaari |
| Lantheus Medical Imaging, INC. | $14.13 | 2024 | |
| Adc Therapeutics America, INC. | $13.85 | 2024 | |
| Janssen Pharmaceuticals, INC | $5.05 | 2023 | Xarelto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Tyler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.